Ines Simeone on Muck Rack

Ines Simeone

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ines

Contact Ines, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma

|
By Elena Splendiani, Zein Mersini Besharat, Claudia Sabato, Maria Fortunata Lofiego, Vincenzo D’alonzo, Mónica Valente, Laura Solmonese, Alessia Covre, Sandra Coral, Francesca Caruso, Ines Simeone, Agnese Po, Anna Citarella, Giuseppina Catanzaro, Roberta Mortarini, Andrea Anichini, Michele Maio, Michele Ceccarelli, Elisabetta Ferretti, Tanja Milena Autilio
| Nature Verified
Abstract Melanoma is the most aggressive skin cancer, with a 50% five-year mortality in metastatic or unresectable cases. Non-invasive biomarkers are crucial for guiding treatment. MicroRNAs (miRNAs), especially those encapsulated in extracellular vesicles (EVs), are stable in plasma and hold promise as biomarkers. This study analyzed EV-associated miRNAs (EV-miRNAs) from 50 blood samples of 18 stage III-IV melanoma patients treated with anti-CTLA-4 immunotherapy and a DNA hypomethylating agent.
Open in Who Shared Issue with article?

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer

|
By François Bertucci, Pascal Finetti, Ines Simeone, Wouter Hendrickx
| Nature Verified
The immunologic constant of rejection (ICR) is a broad phenomenon of Th-1 immunity-mediated, tissue-specific destruction. We tested the prognostic value of a 20-gene ICR expression signature in 8766 early breast cancers. Thirty-three percent of tumours were ICR1, 29% ICR2, 23% ICR3, and 15% ICR4. In univariate analysis, ICR4 was associated with a 36% reduction in risk of metastatic relapse when compared with ICR1-3 (p = 2.30E–03).
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified